Patrick Alexander Ott
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Cutaneous Melanoma Detection and Management
- Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 149
- Cancer Immunotherapy and Biomarkers 113
- CAR-T cell therapy research 56
- Cutaneous Melanoma Detection and Management 16
- Immunology 82
- Immunotherapy and Immune Responses 69
- Immune Cell Function and Interaction 18
- Co-authors
- Frank Stephen Hodi (42 shared papers)Eryn Blass (2 shared papers)Catherine J. Wu (9 shared papers)Zhuting Hu (2 shared papers)Jason J. Luke (17 shared papers)Caroline Robert (1 shared paper)Sarina Anne Piha-Paul (11 shared papers)Sanatan Saraf (6 shared papers)
- Journals
- Journal for ImmunoTherapy of Cancer (22 papers)Annals of Oncology (18 papers)Clinical Cancer Research (10 papers)Journal of Clinical Oncology (10 papers)Cancer Immunology Research (10 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Patrick Alexander Ott
214 papers receiving 31.6k citations
Patrick Alexander Ott's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 20.0k
- Immunology 11.6k
- Cancer Research 2.1k
- Pulmonary and Respiratory Medicine 4.1k
- Molecular Biology 7.6k
Countries citing papers authored by Patrick Alexander Ott
This map shows the geographic impact of Patrick Alexander Ott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Alexander Ott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Alexander Ott more than expected).
Fields of papers citing papers by Patrick Alexander Ott
This network shows the impact of papers produced by Patrick Alexander Ott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Alexander Ott. The network helps show where Patrick Alexander Ott may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Alexander Ott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Hit paper breakdown → | 2015 | 2365 |
| 2 | An immunogenic personal neoantigen vaccine for patients with melanoma Hit paper breakdown → | 2017 | 2347 |
| 3 | Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy Hit paper breakdown → | 2018 | 1795 |
| 4 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial Hit paper breakdown → | 2018 | 1172 |
| 5 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Hit paper breakdown → | 2016 | 1067 |
| 6 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade Hit paper breakdown → | 2018 | 1015 |
| 7 | Towards personalized, tumour-specific, therapeutic vaccines for cancer Hit paper breakdown → | 2017 | 871 |
| 8 | Advances in the development of personalized neoantigen-based therapeutic cancer vaccines Hit paper breakdown → | 2021 | 819 |
| 9 | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Hit paper breakdown → | 2016 | 811 |
| 10 | T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Hit paper breakdown → | 2018 | 761 |
| 11 | CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients Hit paper breakdown → | 2013 | 590 |
| 12 | A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer Hit paper breakdown → | 2020 | 576 |
| 13 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 569 |
| 14 | Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders Hit paper breakdown → | 2015 | 555 |
| 15 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer Hit paper breakdown → | 2018 | 518 |
| 16 | Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors Hit paper breakdown → | 2016 | 513 |
| 17 | Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Hit paper breakdown → | 2017 | 484 |
| 18 | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial Hit paper breakdown → | 2017 | 437 |
| 19 | 2016 | 433 | |
| 20 | Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma Hit paper breakdown → | 2021 | 425 |
About Patrick Alexander Ott
Patrick Alexander Ott is a scholar working on Oncology, Immunology, Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 223 papers that have together received 32.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (113 papers), Immunotherapy and Immune Responses (69 papers), CAR-T cell therapy research (56 papers), Melanoma and MAPK Pathways (29 papers), Immune Cell Function and Interaction (18 papers), vaccines and immunoinformatics approaches (17 papers), Cutaneous Melanoma Detection and Management (16 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). The work is most often cited by research in Oncology (20.0k citations), Immunology (11.6k citations), Cancer Research (2.1k citations), Pulmonary and Respiratory Medicine (4.1k citations) and Molecular Biology (7.6k citations). Patrick Alexander Ott has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Frank Stephen Hodi, Eryn Blass, Catherine J. Wu, Zhuting Hu, Jason J. Luke, Caroline Robert, Sarina Anne Piha-Paul, Sanatan Saraf, Jedd D. Wolchok and Elizabeth Iannotti Buchbinder. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Annals of Oncology, Clinical Cancer Research, Journal of Clinical Oncology and Cancer Immunology Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.